Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s...
NEW YORK, NY / ACCESSWIRE / November 23, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: CoreSite Realty Corporation (NYSE:COR) concerning...
NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) concerning...
In recent trading, shares of Dicerna Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $31.75, changing hands for $38.03/share. When a stock reaches the target an analyst...
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share in cash is fair to Dicerna shareholders....
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Company (“Lilly”) has declared...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today presented results from its Phase 1 double-blind, placebo-controlled,...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended...